Resultats de la cerca - Daniel Mulkerin

  • Mostrar 1 - 11 resultats de 11
Refinar resultats
  1. 1
    A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors

    A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors per Ning Jin, Sam Joseph Lubner, Daniel Mulkerin, Saurabh Rajguru, Lakeesha Carmichael, Herb Chen, Kyle D. Holen, Noelle K. LoConte

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Precision medicine in colorectal cancer: the molecular profile alters treatment strategies

    Precision medicine in colorectal cancer: the molecular profile alters treatment strategies per Nguyen H. Tran, Ludimila Cavalcante, Sam Joseph Lubner, Daniel Mulkerin, Noelle K. LoConte, Linda Clipson, Kristina A. Matkowskyj, Dustin A. Deming

    Publicat 2015
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma

    A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma per Tabraiz A Mohammed, Kyle D. Holen, Renata Jaskula‐Sztul, Daniel Mulkerin, Sam Joseph Lubner, William R. Schelman, Jens C. Eickhoff, Herbert Chen, Noelle K. LoConte

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

    Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-643... per Patricia LoRusso, Karthik Venkatakrishnan, Ramesh K. Ramanathan, John Sarantopoulos, Daniel Mulkerin, Stephen Shibata, Anne Hamilton, Afshin Dowlati, Sridhar Mani, Michelle A. Rudek, Chris H. Takimoto, Rachel Neuwirth, Dixie-Lee Esseltine, S. Percy Ivy

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

    A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer per Dustin A. Deming, Ludimila Cavalcante, Sam Joseph Lubner, Daniel Mulkerin, Noelle K. LoConte, Jens C. Eickhoff, Jill Kolesar, Suzanne Fioravanti, Tim F. Greten, Kathryn Compton, Austin Doyle, George Wilding, Austin G. Duffy, Glenn Liu

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

    Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Org... per Ramesh K. Ramanathan, Merrill J. Egorin, Chris H. Takimoto, Scot C. Remick, James H. Doroshow, Patricia LoRusso, Daniel Mulkerin, Jean L. Grem, Anne Hamilton, Anthony J. Murgo, Douglas M. Potter, Chandra P. Belani, Michael Hayes, Bin Peng, S. Percy Ivy

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

    Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function per Chris H. Takimoto, Martin A. Graham, G. Lockwood, Chee M. Ng, Andrew Goetz, Dennis Greenslade, Scot C. Remick, Sunil Sharma, Sridhar Mani, Ramesh K. Ramanathan, Timothy W. Synold, James H. Doroshow, Anne Hamilton, Daniel Mulkerin, Percy Ivy, Merrill J. Egorin, Jean L. Grem

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

    Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study per Stephen Shibata, Vincent Chung, Timothy W. Synold, Jeff Longmate, A. Benjamin Suttle, Lone H. Ottesen, Heinz-Josef Lenz, Shivaani Kummar, R. Donald Harvey, Anne Hamilton, Bert H. O’Neil, John Sarantopoulos, Patricia LoRusso, Michelle A. Rudek, Afshin Dowlati, Daniel Mulkerin, Chandra P. Belani, Leena Gandhi, S. Cecilia Lau, S. Percy Ivy, Edward M. Newman

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

    Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized... per Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O’Neil, James N. Atkins, Scott Berry, Blasé N. Polite, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter Watson, Al B. Benson, Daniel Mulkerin, Robert J. Mayer, Charles D. Blanke

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

    Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer per Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O’Neil, James N. Atkins, Scott Berry, Blasé N. Polite, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter J. Watson, Al B. Benson, Daniel Mulkerin, Robert J. Mayer, Charles D. Blanke

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity

    Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity per Jeremy D. Kratz, Shujah Rehman, Katherine A. Johnson, Amani A. Gillette, Aishwarya Sunil, Peter F. Favreau, Cheri A. Pasch, Devon Miller, Lucas C. Zarling, Austin H. Yeung, Linda Clipson, Samantha J. Anderson, Alyssa K Steimle, Carley M. Sprackling, Kayla K. Lemmon, Daniel E. Abbott, Mark E. Burkard, M. Bassetti, Jens C. Eickhoff, Eugene F. Foley, Charles P. Heise, Randall J. Kimple, Elise H. Lawson, Noelle K. LoConte, Sam Joseph Lubner, Daniel Mulkerin, Kristina A. Matkowskyj, Cristina B. Sanger, Nataliya V. Uboha, Sean J. McIlwain, Irene M. Ong, Evie H. Carchman, Melissa C. Skala, Dustin A. Deming

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: